|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferro A, Peleteiro B, Malvezzi M, Bosetti
C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N:
Worldwide trends in gastric cancer mortality (1980–2011), with
predictions to 2015, and incidence by subtype. Eur J Cancer.
50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smyth EC and Moehler M: Pembrolizumab in
first-line gastric cancer: Win, lose, or draw? JAMA Oncol.
1:1539–1541. 2020. View Article : Google Scholar
|
|
6
|
Bükakkaramikli NC, Blommestein HM, Riemsma
R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J
and Al MJ: Ramucirumab for treating advanced gastric cancer or
gastro-oesophageal junction adenocarcinoma previously treated with
chemotherapy: An evidence review group perspective of a NICE single
technology appraisal. Pharmacoeconomics. 35:1211–1221. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheong JH, Yang HK, Kim H, Kim WH, Kim YW,
Kook MC, Park YK, Kim HH, Lee HS, Lee KH, et al: Predictive test
for chemotherapy response in resectable gastric cancer: A
multi-cohort, retrospective analysis. Lancet Oncol. 19:629–638.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roh CK, Choi YY, Choi S, Seo WJ, Cho M,
Jang E, Son T, Kim HI, Kim H, Hyung WJ, et al: Single patient
classifier assay, microsatellite instability, and epstein-barr
virus status predict clinical outcomes in stage II/III gastric
cancer: Results from CLASSIC trial. Yonsei Med J. 60:132–139. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi YY, Jang E, Seo WJ, Son T, Kim HI,
Kim HI, Hyung WJ, Huh YM, Noh SH and Cheong JH: Modification of the
TNM staging system for stage II/III gastric cancer based on a
prognostic single patient classifier algorithm. J Gastric Cancer.
18:142–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizoshita T, Tsukamoto T, Cao X, Otsuka T,
Ito S, Takahashi E, Nakamura S, Nakamura T, Yamamura Y and
Tatematsu M: Microsatellite instability is linked to loss of hMLH1
expression in advanced gastric cancers: Lack of a relationship with
the histological type and phenotype. Gastric Cancer. 8:164–172.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ionov Y, Peinado MA, Malkhosyan S, Shibata
D and Perucho M: Ubiquitous somatic mutations in simple repeated
sequences reveal a new mechanism for colonic carcinogenesis.
Nature. 363:558–561. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A national cancer institute
workshop on microsatellite instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
16
|
Hause RJ, Pritchard CC, Shendure J and
Salipante SJ: Classification and characterization of microsatellite
instability across 18 cancer types. Nat Med. 22:1342–1350. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang WL, Chen MH, Huang KH, Chang SC, Lin
CH, Chao Y, Lo SS, Li AF, Wu CW and Shyr YM: The
clinicopathological features and genetic mutations in gastric
cancer patients according to EMAST and MSI status. Cancers (Basel).
27:5512020. View Article : Google Scholar
|
|
18
|
An JY, Kim H, Cheong JH, Hyung WJ, Kim H
and Noh SH: Microsatellite instability in sporadic gastric cancer:
Its prognostic role and guidance for 5-FU based chemotherapy after
R0 resection. Int J Cancer. 131:505–511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gurzu S, Jung I, Sugimura H, Stefan-van
Staden RI, Yamada H, Natsume H, Iwashita Y, Szodorai R and
Szederjesi J: Maspin subcellular expression in wild-type and mutant
TP53 gastric cancers. World J Gastrointest Oncol. 15:741–755. 2020.
View Article : Google Scholar
|
|
20
|
Kanayama K, Imai H, Usugi E, Matsuda C,
Ichishi M, Hirokawa YS and Watanabe M: Cancer-Related gene
mutations and intratumoral genetic heterogeneity in human epidermal
growth factor receptor 2 heterogeneous gastric cancer. Pathol Int.
70:865–870. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grundei T, Vogelsang H, Ott K, Mueller J,
Scholz M, Becker K, Fink U, Siewert JR, Höfler H and Keller G: Loss
of heterozygosity and microsatellite instability as predictive
markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer
Res. 6:4782–4788. 2000.PubMed/NCBI
|
|
22
|
Chang SC, Lin JK, Lin TC and Liang WY:
Loss of heterozygosity: An independent prognostic factor of
colorectal cancer. World J Gastroenterol. 11:7787842005. View Article : Google Scholar
|
|
23
|
Lin X, Zhao Y, Song WM and Zhang B:
Molecular classification and prediction in gastric cancer. Comput
Struct Biotechnol J. 13:448–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du X, Chen Z, Li W, Tan Y, Lu J, Zhu X,
Zhao T, Dong G and Zeng L: Development of novel microsatellite DNA
markers by cross-amplification and analysis of genetic variation in
gerbils. J Hered. 101:710–716. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Plevová P: An update on inherited colon
cancer and gastrointestinal polyposis. Klin Onkol. 32:97–108. 2019.
View Article : Google Scholar
|
|
26
|
Yamamoto H and Imai K: Microsatellite
instability: An update. Arch Toxicol. 89:899–921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J
and Sung JJ: Dysregulation of cellular signaling in gastric cancer.
Cancer Lett. 28:144–153. 2010. View Article : Google Scholar
|
|
28
|
Yan LH, Wei WY, Xie YB and Xiao Q: New
insights into the functions and localization of the homeotic gene
CDX2 in gastric cancer. World J Gastroenterol. 14:3960–3966. 2014.
View Article : Google Scholar
|
|
29
|
Xanthoulis A and Tiniakos DG: E2F
transcription factors and digestive system malignancies: How much
do we know? World J Gastroenterol. 19:3189–3198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu H, Li C, Cai S, Zhu C, Tian Y, Zheng J,
Hu J, Chen C and Liu W: Increased expression of pleiotrophin is a
prognostic marker for patients with gastric cancer.
Hepatogastroenterology. 61:1478–1482. 2014.PubMed/NCBI
|
|
31
|
Hu H, Song Z, Yao Q, Geng X, Jiang L, Guo
C and Li H: Proline-Rich protein 11 regulates self-renewal and
tumorigenicity of gastric cancer stem cells. Cell Physiol Biochem.
47:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lotem J, Levanon D, Negreanu V, Bauer O,
Hantisteanu S, Dicken J and Groner Y: Runx3 in immunity,
inflammation and cancer. Adv Exp Med Biol. 962:369–393. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huo X, Zhang S, Li Z, Gao J, Wang C, Li C,
Guo M, Du X and Chen Z: Analysis ofthe relationship between
microsatellite instability and thymic lymphoma induced by
methyl-N-nitrosourea in C57BL/6J mice. Mut Res. 771:21–28. 2015.
View Article : Google Scholar
|
|
34
|
Fujimoto A, Fujita M, Hasegawa T, Wong JH,
Maejima K, Oku-Sasaki A, Nakano K, Shiraishi Y, Miyano S, Yamamoto
G, et al: Comprehensive analysis of indels in whole-genome
microsatellite regions and microsatellite instability across 21
cancer types. Genome Res. 24:334–346. 2020. View Article : Google Scholar
|
|
35
|
Huang KH, Chen MH, Fang WL, Lin CH, Chao
Y, Lo SS, Li AF, Wu CW and Shyr YM: The clinicopathological
characteristics and genetic alterations of signet-ring cell
carcinoma in gastric cancer. Cancers (Basel). 17:23182020.
View Article : Google Scholar
|
|
36
|
Marrelli D, Polom K, Pascale V, Vindigni
C, Piagnerelli R, De Franco L, Ferrara F, Roviello G, Garosi L,
Petrioli R and Roviello F: Strong prognostic value of
microsatellite instability in intestinal type non-cardia gastric
cancer. Ann Surg Oncol. 23:943–950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Angell HK, Lee J, Kim KM, Kim K, Kim ST,
Park SH, Kang WK, Sharpe A, Ogden J and Davenport A: PD-L1 and
immune infiltrates are differentially expressed in distinct
subgroups of gastric cancer. Oncoimmunology. 8:e15444422018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi YY, Bae JM, An JY, Kwon IG, Cho I,
Shin HB, Eiji T, Aburahmah M, Kim HI, Cheong JH, et al: Is
microsatellite instability a prognostic marker in gastric cancer? A
systematic review with meta-analysis. J Surg Oncol. 110:129–135.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Falchetti M, Saieva C, Lupi R, Masala G,
Rizzolo P, Zanna I, Ceccarelli K, Sera F, Mariani-Costantini R,
Nesi G, et al: Gastric cancer with high-level microsatellite
instability: Target gene mutations, clinicopathologic features, and
long-term survival. Hum Pathol. 39:925–932. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hayden JD, Cawkwell L, Quirke P, Dixon MF,
Goldstone AR, Sue-Ling H, Johnston D and Martin IG: Prognostic
significance of microsatellite instability in patients with gastric
carcinoma. Eur J Cancer. 33:2342–2346. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu MS, Lee CW, Sheu JC, Shun CT, Wang HP,
Hong RL, Lee WJ and Lin JT: Alterations of BAT-26 identify a subset
of gastric cancer with distinct clinicopathologic features and
better postoperative prognosis. Hepatogastroenterology. 49:285–289.
2002.PubMed/NCBI
|
|
42
|
Corso G, Velho S, Paredes J, Pedrazzani C,
Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M,
et al: Oncogenic mutations in gastric cancer with microsatellite
instability. Eur J Cancer. 47:443–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leite M, Corso G, Sousa S, Milanezi F,
Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello
F, et al: MSI phenotype and MMR alterations in familial and
sporadic gastric cancer. Int J Cancer. 128:1606–1613. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maruvka YE, Mouw KW, Karlic R, Parasuraman
P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody
Y, et al: Analysis of somatic microsatellite indels identifies
driver events in human tumors. Nat Biotechnol. 35:951–959. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim DG, An JY, Kim H, Shin SJ, Choi S, Seo
WJ, Roh CK, Cho M, Son T, Kim HI, et al: Clinical implications of
microsatellite instability in early gastric cancer. J Gastric
Cancer. 19:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim JY, Shin NR, Kim A, Lee HJ, Park WY,
Kim JY, Lee CH, Huh GY and Park DY: Microsatellite instability
status in gastric cancer: A reappraisal of its clinical
significance and relationship with mucin phenotypes. Korean J
Pathol. 47:28–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin JT, Wu MS, Shun CT, Lee WJ, Wang JT,
Wang TH and Sheu JC: Microsatellite instability in gastric
carcinoma with special references to histopathology and cancer
stages. Eur J Cancer. 31A:1879–1882. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Suraweera N, Duval A, Reperant M, Vaury C,
Furlan D, Leroy K, Seruca R, Iacopetta B and Hamelin R: Evaluation
of tumor microsatellite instability using five quasimonomorphic
mononucleotide repeats and pentaplex PCR. Gastroenterology.
123:1804–1811. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huo X, Xiao X, Zhang S, Zhou D and Chen Z:
Association of intron microsatellite instability and exon
mutational profile of TP53 in human gastric cancers. Anticancer
Res. 37:4507–4514. 2017.PubMed/NCBI
|
|
50
|
Liu X, Feng D, Huo X, Xiao X and Chen Z:
Association of intron microsatellite status and exon mutational
profiles of TP53 in human colorectal cancer. Exp Ther Med.
18:4287–4294. 2019.PubMed/NCBI
|
|
51
|
Polom K, Marano L, Marrelli D, De Luca R,
Roviello G, Savelli V, Tan P and Roviello F: Meta-Analysis of
microsatellite instability in relation to clinicopathological
characteristics and overall survival in gastric cancer. Br J Surg.
105:159–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
An JY, Min JS, Lee YJ, Jeong SH, Hur H,
Han SU, Hyung WJ, Cho GS, Jeong GA, Jeong O, et al: Safety of
laparoscopic sentinel basin dissection in patients with gastric
cancer: An analysis from the SENORITA prospective multicenter
quality control trial. J Gastric Cancer. 18:30–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Choi J, Nam SK, Park DJ, Kim HW, Kim HH,
Kim WH and Lee HS: Correlation between microsatellite
instability-high phenotype and occult lymph node metastasis in
gastric carcinoma. APMIS. 123:215–222. 2015. View Article : Google Scholar : PubMed/NCBI
|
